Multiple Myeloma (MM) is a common blood cancer. Multiple Myeloma patients suffer from several disease- or treatment-related symptoms. Thus, symptom management is an important part of treating MM, and easing symptoms helps in improving patients’ quality of life. Digital symptom tracking has been shown to improve overall survival and quality of life amongst metastatic cancer patients undergoing chemotherapy. However, a similar approach has not been adapted for supporting Multiple Myeloma patients.
In order to bridge this unmet need, Finnish health data science company Kaiku Health that develops personalised digital health interventions in oncology, and one of the world’s leading biotechnology companies Amgen have partnered to advance the use of digital symptom management and personalised patient support in routine care of Multiple Myeloma in Finland.